Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom.

Stephan Schueler Scott C SilvestryWilliam G CottsMark S SlaughterWayne C Levy Richard K ChengJennifer A BeckmanJonas VillingerEleni IsmyrloglouStelios I Tsintzos Claudius Mahr

Published in: ESC heart failure (2021)

The implantation of the HeartWare™ HVAD™ System in patients ineligible for cardiac transplantation as DT is a cost-effective therapy in the NHS England healthcare system under the end-of-life willingness-to-pay threshold of £50 000/QALY, which applies for VAD patients.

Keyphrases

end stage renal disease
left ventricular
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
mesenchymal stem cells
bone marrow
acute coronary syndrome
hypertrophic cardiomyopathy
patient reported